A sales subsidiary of Shenzhen-listed Wepon has been fined for imposing unreasonable trading conditions on the sale of the active pharmaceutical ingredient, or API, bromhexine hydrochloride. Wepon Group Zhejiang Pharmaceutical Sales was fined 2,241,754 yuan ($341,960), equivalent to 3 percent of its revenue for 2019, and had 232,205 yuan in illegal gains